Patents by Inventor Lizbeth K. Hedstrom
Lizbeth K. Hedstrom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180327364Abstract: Disclosed are small molecule inhibitors of mammalian target of rapamycin (mTOR), and methods of using them.Type: ApplicationFiled: November 14, 2016Publication date: November 15, 2018Inventors: Ann Parrinello Lawson, Jianjun Xue, Lizbeth K. Hedstrom, Rory T. Coffey
-
Patent number: 10125116Abstract: Described herein are compounds, and pharmaceutically acceptable salts and prodrugs thereof, which are useful as inhibitors of IMPDH. In certain embodiments, a compound of the invention selectively inhibits a parasitic IMPDH versus a host IMPDH. Further, the invention provides pharmaceutical compositions comprising one or more compounds of the invention. The invention also relates to methods of treating various parasitic and bacterial infections in mammals. Moreover, the compounds may be used alone or in combination with other therapeutic or prophylactic agents, such as anti-virals, anti-inflammatory agents, antimicrobials and immunosuppressants.Type: GrantFiled: December 16, 2014Date of Patent: November 13, 2018Assignees: Brandeis University, University of Georgia Research Foundation, Inc., The Brigham and Women's Hospital, Inc.Inventors: Lizbeth K. Hedstrom, Gregory D. Cuny, Deviprasad R. Gollapalli, Sivapriya Kirubakaran, Sushil K. Maurya, Boris Striepen, Suresh K. Gorla, Corey R. Johnson, Mandapati Kavitha, Jihan Khan
-
Patent number: 10125162Abstract: Described herein are oligosaccharide-oligonucleotide conjugates useful as vaccines against one or more human or veterinary therapeutic indications, and methods of synthesizing and identifying them. The conjugates may be identified using non-human antibodies as binding targets, thereby expanding the power and scope of the invention. Efficacious conjugates may be identified through an iterative screening process.Type: GrantFiled: June 19, 2015Date of Patent: November 13, 2018Assignee: Brandeis UniversityInventors: Isaac J. Krauss, Lizbeth K. Hedstrom, Iain S. MacPherson
-
Patent number: 10017463Abstract: Disclosed are small molecule inhibitors of deubiquitinating enzymes (DUBs), and methods of using them. Certain compounds are selective for particular ubiquitin-specific proteases (USPs).Type: GrantFiled: July 21, 2015Date of Patent: July 10, 2018Assignee: Brandeis UniversityInventors: Lizbeth K. Hedstrom, Marcus J. Long, Ann Parrinello Lawson
-
Patent number: 9765019Abstract: Certain aspects of the invention relate to compounds, compositions and methods that are useful for treating or preventing a disease in a subject by enhancing the degradation of a protein. In other aspects, said compounds can be useful research tools for investigating protein degradation. In other aspects, said compounds are useful research tools for investigating protein function. In certain embodiments, the degraded protein is implicated in a disease or disorder whose pathology is related at least in part to the excessive expression of the protein or the expression of a mutant form of the protein.Type: GrantFiled: June 30, 2011Date of Patent: September 19, 2017Assignee: Brandeis UniversityInventors: Lizbeth K. Hedstrom, Marcus Long, Deviprasad R. Gollapalli
-
Publication number: 20170204055Abstract: Disclosed are small molecule inhibitors of deubiquitinating enzymes (DUBs), and methods of using them. Certain compounds are selective for particular ubiquitin-specific proteases (USPs).Type: ApplicationFiled: July 21, 2015Publication date: July 20, 2017Applicant: Brandeis UniversityInventors: Lizbeth K. Hedstrom, Marcus J. Lonh, Ann Lawson
-
Patent number: 9447134Abstract: Disclosed are compounds and pharmaceutically acceptable salts thereof, which are useful as inhibitors of IMPDH. In certain embodiments, a compound selectively inhibits a parasitic IMPDH versus a host IMPDH. Also disclosed are pharmaceutical compositions comprising one or more compounds of the invention. Related methods of treating various parasitic and bacterial infections in mammals are disclosed. Moreover, the compounds may be used alone or in combination with other therapeutic or prophylactic agents, such as anti-virals, anti-inflammatory agents, antimicrobials and immunosuppressants.Type: GrantFiled: August 19, 2013Date of Patent: September 20, 2016Assignees: Brandeis University, The Brigham and Women's Hospital, Inc.Inventors: Lizbeth K. Hedstrom, Gregory D. Cuny, Suresh K. Gorla, Mandapati Kavitha
-
Publication number: 20160090351Abstract: Disclosed are small molecule inhibitors of deubiquitinating enzymes (DUBs), and methods of using them. Certain compounds display a preference for specific ubiquitin specific proteases (USPs).Type: ApplicationFiled: April 18, 2014Publication date: March 31, 2016Inventors: Lizbeth K. Hedstrom, Marcus John Curtis Long, Ricky Francis Baggio, Ann Parrinello Lawson
-
Publication number: 20160051690Abstract: Described herein are oligosaccharide-oligonucleotide conjugates useful as vaccines against one or more human or veterinary therapeutic indications, and methods of synthesizing and identifying them. The conjugates may be identified using non-human antibodies as binding targets, thereby expanding the power and scope of the invention. Efficacious conjugates may be identified through an iterative screening process.Type: ApplicationFiled: June 19, 2015Publication date: February 25, 2016Inventors: Isaac J. KRAUSS, Lizbeth K. HEDSTROM, Iain S. MACPHERSON
-
Publication number: 20150210727Abstract: Disclosed are compounds and pharmaceutically acceptable salts thereof, which are useful as inhibitors of IMPDH. In certain embodiments, a compound selectively inhibits a parasitic IMPDH versus a host IMPDH. Also disclosed are pharmaceutical compositions comprising one or more compounds of the invention. Related methods of treating various parasitic and bacterial infections in mammals are disclosed. Moreover, the compounds may be used alone or in combination with other therapeutic or prophylactic agents, such as anti-virals, anti-inflammatory agents, antimicrobials and immunosuppressants.Type: ApplicationFiled: August 19, 2013Publication date: July 30, 2015Applicant: The Brigham and Women's Hospital, Inc.Inventors: Lizbeth K. Hedstrom, Gregory D. Cuny, Suresh K. Gorla, Mandapati Kavitha
-
Patent number: 9080169Abstract: Described herein are oligosaccharide-oligonucleotide conjugates useful as vaccines against one or more human or veterinary therapeutic indications, and methods of synthesizing and identifying them. The conjugates may be identified using non-human antibodies as binding targets, thereby expanding the power and scope of the invention. Efficacious conjugates may be identified through an iterative.Type: GrantFiled: June 10, 2011Date of Patent: July 14, 2015Assignee: Brandeis UniversityInventors: Isaac Jonathan Krauss, Lizbeth K. Hedstrom, Iain S. MacPherson
-
Publication number: 20150099781Abstract: Described herein are compounds, and pharmaceutically acceptable salts and prodrugs thereof, which are useful as inhibitors of IMPDH. In certain embodiments, a compound of the invention selectively inhibits a parasitic IMPDH versus a host IMPDH. Further, the invention provides pharmaceutical compositions comprising one or more compounds of the invention. The invention also relates to methods of treating various parasitic and bacterial infections in mammals. Moreover, the compounds may be used alone or in combination with other therapeutic or prophylactic agents, such as anti-virals, anti-inflammatory agents, antimicrobials and immunosuppressants.Type: ApplicationFiled: December 16, 2014Publication date: April 9, 2015Inventors: Lizbeth K. Hedstrom, Gregory D. Cuny, Deviprasad R. Gollapalli, Sivapriya Kirubakaran, Sushil K. Maurya, Boris Striepen, Suresh K. Gorla, Corey R. Johnson, Mandapati Kavitha, Jihan Khan
-
Patent number: 8969342Abstract: Described herein are compounds, and pharmaceutically acceptable salts and prodrugs thereof, which are useful as inhibitors of IMPDH. In certain embodiments, a compound of the invention selectively inhibits a parasitic IMPDH versus a host IMPDH. Further, the invention provides pharmaceutical compositions comprising one or more compounds of the invention. The invention also relates to methods of treating various parasitic and bacterial infections in mammals. Moreover, the compounds may be used alone or in combination with other therapeutic or prophylactic agents, such as anti-virals, anti-inflammatory agents, antimicrobials and immunosuppressants.Type: GrantFiled: March 22, 2010Date of Patent: March 3, 2015Assignees: Brandeis University, University of Georgia Research Foundation, Inc., The Brigham and Women's Hospital, Inc.Inventors: Lizbeth K. Hedstrom, Gregory D. Cuny, Deviprasad R. Gollapalli, Boris Striepen, Suresh Kumar Gorla, Mandapati Kavitha
-
Publication number: 20130190340Abstract: Certain aspects of the invention relate to compounds, compositions and methods that are useful for treating or preventing a disease in a subject by enhancing the degradation of a protein. In other aspects, said compounds can be useful research tools for investigating protein degradation. In other aspects, said compounds are useful research tools for investigating protein function. In certain embodiments, the degraded protein is implicated in a disease or disorder whose pathology is related at least in part to the excessive expression of the protein or the expression of a mutant form of the protein.Type: ApplicationFiled: June 30, 2011Publication date: July 25, 2013Applicant: Brandeis UniversityInventors: Lizbeth K. Hedstrom, Marcus Long, Deviprasad R. Gollapalli
-
Publication number: 20130116417Abstract: Described herein are oligosaccharide-oligonucleotide conjugates useful as vaccines against one or more human or veterinary therapeutic indications, and methods of synthesizing and identifying them. The conjugates may be identified using non-human antibodies as binding targets, thereby expanding the power and scope of the invention. Efficacious conjugates may be identified through an iterative.Type: ApplicationFiled: June 10, 2011Publication date: May 9, 2013Applicant: BRANDEIS UNIVERSITYInventors: Isaac J. Krauss, Lizbeth K. Hedstrom, Iain S. MacPherson
-
Publication number: 20120264760Abstract: One aspect of the present invention relates to compounds, and pharmaceutically acceptable salts and prodrugs thereof, that are useful as inhibitors of IMPDH. The invention also provides pharmaceutical compositions comprising the compounds of the invention which selectively inhibit parasitic IMPDH. In certain embodiments, the present invention relates to selective inhibition of C. parvum inosine-5?-monophosphate-dehydrogenase over human inosine-5?-monophosphate-dehydrogenase (IMPDH type I and type II). These compounds may be used alone or in combination with other therapeutic or prophylactic agents, such as anti-virals, anti-inflammatory agents, antimicrobials and immunosuppressants.Type: ApplicationFiled: June 6, 2012Publication date: October 18, 2012Applicants: University of Georgia Research Foundation, Inc., Brandeis UniversityInventors: Lizbeth K. Hedstrom, Boris Striepen
-
Publication number: 20120101096Abstract: Described herein are compounds, and pharmaceutically acceptable salts and prodrugs thereof, which are useful as inhibitors of IMPDH. In certain embodiments, a compound of the invention selectively inhibits a parasitic IMPDH versus a host IMPDH. Further, the invention provides pharmaceutical compositions comprising one or more compounds of the invention. The invention also relates to methods of treating various parasitic and bacterial infections in mammals. Moreover, the compounds may be used alone or in combination with other therapeutic or prophylactic agents, such as anti-virals, anti-inflammatory agents, antimicrobials and immunosuppressants.Type: ApplicationFiled: March 22, 2010Publication date: April 26, 2012Applicants: University of Georgia Foundation, Inc., Brandeis UniversityInventors: Lizbeth K. Hedstrom, Gregory D. Cuny, Deviprasad R. Gollapalli, Sivapriya Kirubakaran, Sushil Kumar Maurya, Boris Striepen, Suresh Kumar Gorla, Corey Robert Johnson, Mandapati Kavitha, Jihan Khan
-
Publication number: 20100022547Abstract: One aspect of the present invention relates to compounds, and pharmaceutically acceptable salts and prodrugs thereof, that are useful as inhibitors of IMPDH. The invention also provides pharmaceutical compositions comprising the compounds of the invention which selectively inhibit parasitic IMPDH. In certain embodiments, the present invention relates to selective inhibition of C. parvum inosine-5?-monophosphate-dehydrogenase over human inosine-5?-monophosphate-dehydrogenase (IMPDH type I and type II). These compounds may be used alone or in combination with other therapeutic or prophylactic agents, such as anti-virals, anti-inflammatory agents, antimicrobials and immunosuppressants.Type: ApplicationFiled: June 1, 2007Publication date: January 28, 2010Applicants: BRANDEIS UNIVERSITY, UNIVERSITY OF GEORFIA RESEARCH FOUNDATIONInventors: Lizbeth K. Hedstrom, Boris Striepen